Analysis of factors contributing to the low survival of cervical cancer patients undergoing radiotherapy in Kenya

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Maranga, Innocent O ^a,b   Hampson, Lynne ^a   Oliver, Anthony W ^a   Gamal, Anas ^d   Gichangi, Peter ^b   Opiyo, Anselmy ^c   Holland, Catharine M ^a   Hampson, Ian N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c KENYATTA NATIONAL HOSPITAL   (Kenya)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HEMOGLOBIN;

ACUTE TOXICITY; ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANAPLASTIC CARCINOMA; ARTICLE; AWARENESS; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INVASIVE CERVICAL CANCER; KENYA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROSPECTIVE STUDY; SARCOMA; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; ADJUVANT CHEMOTHERAPY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; RADIATION DOSE; RADIOTHERAPY; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KENYA; LOST TO FOLLOW-UP; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84906052438     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078411     Document Type: Article

References (57)

1. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
2. WHO (2004) The global burden of disease: 2004 update-Annex A: WHO, 2004 Deaths and DALYs 2004 Annex tables. Available at https://extranet.who. int/iris/restricted/bitstream/10665/43942/1/9789241563710-eng.pdf Accessed 4th October 2013.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2008) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
4. Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97: 72-81.
5. WHO (1996) Cervical cancer control in developing countries: memorandum from a WHO meeting. Bull World Health Organ 74: 345-351.
6. WHO I (2007) Cancer Incidence in Five Continents. In: Curado MP EB, Shin HR, StormH, Ferlay J, Heanue M, Boyle P, Lyon: IARC Scientific Publications.
7. Kitchener HC, Hoskins W, Small W Jr, Thomas GM, Trimble EL (2010) The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report. Int J Gynecol Cancer 20: 1092-1100.
8. Aniebue PN, Aniebue UU (2010) Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. J Cancer Educ 25: 106-108.
9. Anorlu RI (2008) Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters 16: 41-49.
10. Dim CC, Dim NR, Ezegwui HU, Ikeme AC (2009) An unmet cancer screening need of HIV-positive women in southeastern Nigeria. Medscape J Med 11: 19.
11. Gichangi P, Bwayo J, Estambale B, Rogo K, Njuguna E, et al. (2006) HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer. Gynecol Oncol 100: 405-411.
12. Samant R, Kobeleva S, Choan E, Balaraj K, Tien Le, et al. (2010) Evaluating Contemporary Radiotherapy Approachesin the Primary Treatment of Cervical Cancer. Int J Gynecol Cancer: 1087-1091.
13. Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, et al. (1995) The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 32: 1301-1307.
14. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, et al. (1999) A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 73: 177-183.
15. Cox J (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341-1346.
16. King M, McConkey C, Latief TN, Hartley A, Fernando I (2006) Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol) 18: 38-45.
17. Eifel PJ (2006) Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nat Clin Pract Oncol 3: 248-255.
18. Berclaz G, Gerber E, Beer K, Aebi S, Greiner R, et al. (2002) Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-Year survival after radiochemotherapy. Int J Oncol 20: 1313-1318.
19. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, et al. (2004) Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22: 872-880.
20. Shanta V, Selvaluxmy G, Swaminathan R, Shanthi P (1091) Evolution in the management of locally advanced cervical cancer: the experience of Cancer Institute (WIA), Chennai, India. Asian Pac J Cancer Prev 11: 1091-1098.
21. Pearcey R, Miao Q, Kong W, Zhang-Salomons J, Mackillop WJ (2007) Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study. J Clin Oncol 25: 2383-2388.
22. Kesic V (2006) Management of cervical cancer. Eur J Surg Oncol 32: 832-837.
23. Vale CL, Tierney JF, Davidson SE, Drinkwater KJ, Symonds P (2010) Substantial improvement in UK cervical cancer survival with chemoradiother-apy: results of a Royal College of Radiologists' audit. Clin Oncol (R Coll Radiol) 22: 590-601.
24. McArdle O, Kigula-Mugambe JB (2007) Contraindications to cisplatin based chemoradiotherapy in the treatment of cervical cancer in Sub-Saharan Africa. Radiother Oncol 83: 94-96.
25. Gatune JW, Nyamongo IK (2005) An ethnographic study of cervical cancer among women in rural Kenya: is there a folk causal model? Int J Gynecol Cancer 15: 1049-1059.
26. Gichangi P, Estambale B, Bwayo J, Rogo K, Ojwang S, et al. (2003) Knowledge and practice about cervical cancer and Pap smear testing among patients at Kenyatta National Hospital, Nairobi, Kenya. Int J Gynecol Cancer 13: 827-833.
27. Dim CC, Nwagha UI, Ezegwui HU, Dim NR (2009) The need to incorporate routine cervical cancer counselling and screening in the management of women at the outpatient clinics in Nigeria. J Obstet Gynaecol 29: 754-756.
28. Spence AR, Goggin P, Franco EL (2007) Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med 45: 93-106.
29. Claeys P, Gonzalez C, Gonzalez M, Page H, Bello RE, et al. (2002) Determinants of cervical cancer screening in a poor area: results of a population-based survey in Rivas, Nicaragua. Trop Med Int Health 7: 935-941.
30. Watkins MM, Gabali C, Winkleby M, Gaona E, Lebaron S (2002) Barriers to cervical cancer screening in rural Mexico. Int J Gynecol Cancer 12: 475-479.
31. Wong LP, Wong YL, Low WY, Khoo EM, Shuib R (2008) Cervical cancer screening attitudes and beliefs of Malaysian women who have never had a pap smear: a qualitative study. Int J Behav Med 15: 289-292.
32. Louie KS, de Sanjose S, Mayaud P (2009) Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop Med Int Health 14: 1287-1302.
33. Ndlovu N, Kambarami R (2003) Factors associated with tumour stage at presentation in invasive cervical cancer. Cent Afr J Med 49: 107-111.
34. Kidanto HL, Kilewo CD, Moshiro C (2002) Cancer of the cervix: knowledge and attitudes of female patients admitted at Muhimbili National Hospital, Dar es Salaam. East Afr Med J 79: 467-475.
35. MMH (2007) Cervical Cancer: Cancers of the Female Reproductive System. Available at http://www.merckmanuals.com/home/womens-health-issues/cance rs- of-the-f emale-r eproductive-syst em/cervical-cancer. html?qt=&sc=&alt= Accessed 4th October 2013.
36. Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, et al. (2004) Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 90: 1367-1373.
37. Brookfield KF, Cheung MC, Lucci J, Fleming LE, Koniaris LG (2009) Disparities in survival among women with invasive cervical cancer: a problem of access to care. Cancer 115: 166-178.
38. Engin G, Kucucuk S, Olmez H, Hasiloglu ZI, Disci R, et al. (2011) Correlation of clinical and MRI staging in cervical carcinoma treated with radiation therapy: a single-center experience. Diagn Interv Radiol 17: 44-51.
39. Kodaira T, Fuwa N, Toita T, Nomoto Y, Kuzuya K, et al. (2003) Comparison of prognostic value of MRI and FIGO stage among patients with cervical carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 56: 769-777.
40. Teh J, Yap SP, Tham I, Sethi VK, Chua EJ, et al. (2010) Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors. Int J Gynecol Cancer 20: 428-433.
41. Subak LL, Hricak H, Powell CB, Azizi L, Stern JL (1995) Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol Cross Ref Medline: 43-50.
42. Eifel PJ, Berek JS, Thigpen JT (1997) Cancer of the cervix, vagina, and vulva. In: DeVita VT, Hellman S, Rosenberg SA, Cancer: principles and practice of oncology. Philadelphia, Pa: Lippincott: 1433-1475.
43. Maduro JH, Pras E, Willemse PH, de Vries EG (2003) Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 29: 471-488.
44. Candelaria M, Cetina L, Duenas-Gonzalez A (2005) Anemia in cervical cancer patients: implications for iron supplementation therapy. Medical Oncology 22/2: 1357-0560.
45. Brizel DM, Dodge RK, Clough RW, Dewhirst MW (1999) Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol: 113-117.
46. Nordsmark M, Overgaard M, Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol: 31-40
47. Brown J, Wilson RW (2004) exploiting tumour hypoxia in cancer treatment. Nature Reviews | Cancer 4.
48. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nature Rev Cancer 38-47.
49. Gichangi P, De Vuyst H, Estambale B, Rogo K, Bwayo J, et al. (2002) HIV and cervical cancer in Kenya. Int J Gynaecol Obstet 76: 55-63.
50. Maiman M, Fruchter RG, Clark M, Arrastia CD, Matthews R, et al. (1997) Cervical cancer as an AIDS-defining illness. Obstet Gynecol: 76-80.
51. Korn AP, Abercrombie PD (1997) Gynecology and family planning care for women infected with HIV. Obstet Gynecol Clin North AM: 855-872.
52. Rellihan M, Dooley D, Burke T, Berkland ME, Longfield RN (1990) Rapidly progressing cervical cancer in a patient with human Immunodeficiency infection. Gynecol Oncol 435.
53. Schwartz L, Carcangui M, Bradham L, Schwartz PE (1991) Rapidly progressive squamous cell carcinoma of the Cervix coexisting with HIV infection:Clinical opinion. Gynecol Oncol: 225.
54. Survey KDH (2009) HIV Prevalence in Kenya. Available at http://www.measuredhs.com/pubs/pdf/GF17/GF17.pdf Accessed 4th October 2013.
55. Obi SN, Ozumba BC (2008) Cervical cancer: socioeconomic implications of management in a developing nation. J Obstet Gynaecol 28: 526-528.
56. Harford JB, Edwards BK, Nandakumar A, Ndom P, Capocaccia R, et al. (2009) Cancer control-planning and monitoring population-based systems. Tumori 95: 568-578.
57. Okwo-Bele JM, Cherian T (2011) The expanded programme on immunization: a lasting legacy of smallpox eradication. Vaccine 29 Suppl 4: D74-79.